Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
WRIC Richmond on MSN1d
FDA approves first opioid-free painkiller in over two decadesThe U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...
JOURNAVX can cause side effects: The most common side effects for patients treated with JOURNAVX include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback